The in vitro colony assay: a predictor of clinical outcome.
OBJECTIVE
To determine the predictive power of an in vitro colony assay on the clinical normal-tissue complication rate.


METHODS
Primary skin fibroblasts from 88 individuals were generated from the skin biopsies of patients who received a standardized radiotherapy. Tissue was cultured for three to six passages, irradiated with doses between 1 and 8 Gy under defined conditions, seeded and finally the colonies were stained and counted after 10-14 days. The survival curves were fitted by the L-Q model and the SF2, alpha/beta and plating efficiency were calculated.


RESULTS
The parameters SF2 and plating efficiency were stable throughout the 4-year test period. Intra-individual differences between repeated experiments were significantly lower than inter-individual test results. For the observed acute skin and late normal-tissue reactions other than skin the in vitro parameter SF2 correlated significantly (p<0.005). For late skin reactions this correlation was not found.


CONCLUSIONS
In contrast to other publications, a clear correlation was found between the in vitro test results and clinically observed early reactions. The lack of correlation for late skin reactions suggests that the combination of intrinsic radiation sensitivity and exogenous factors may alter the clinically observed reaction of certain tissues to a different extent.
Oppitz
U
U
Department of Radiation Therapy, University of Würzburg, Germany. oppitz@strahlentherapie.uni-wuerzburg.de
Baier
K
K
Wulf
J
J
Schakowski
R
R
Flentje
M
M
D001943:Breast Neoplasms / Q000532:radiotherapy; D018929:Cell Culture Techniques / Q000379:methods*; D002470:Cell Survival / Q000528:radiation effects; D002478:Cells, Cultured; D004307:Dose-Response Relationship, Radiation; D005347:Fibroblasts / Q000166:cytology / Q000378:metabolism; D006801:Humans; D009369:Neoplasms / Q000532:radiotherapy*; D011878:Radiotherapy / Q000379:methods*; D012867:Skin / Q000166:cytology / Q000378:metabolism; D013997:Time Factors; D016896:Treatment Outcome